Inhaled iloprost for therapy in pulmonary arterial hypertension

Expert Review of Respiratory Medicine

Volumn 5, Issue 2, 2011, Pages 145-152

  Ewert, Ralf ^a   Gläser, Sven ^a   Bollmann, Tom ^a   Schäper, Christoph ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

inhaled iloprost; PAH; prostanoids; side effects of therapy; therapy algorithm

Indexed keywords

BOSENTAN; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; TOLAFENTRIN; UNCLASSIFIED DRUG;

ADD ON THERAPY; BRONCHUS OBSTRUCTION; CLINICAL TRIAL (TOPIC); COUGHING; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXERCISE; FLUSHING; HEADACHE; HEART OUTPUT; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; JAW PAIN; MULTICENTER STUDY (TOPIC); PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; SYNCOPE; THORAX PAIN; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT RESPONSE; VASCULAR RESISTANCE; XEROSTOMIA;

EID: 79955402205     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.14     Document Type: Review

References (64)

1. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54, S43-S54 (2009).
2. Badesch DB, Champion HC, Gomez Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S55-S66 (2009).
3. Galié N, Hoeper MM, Humbert M et al. Guidelines for diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 30, 2493-2537 (2009).
4. Schulz A. Pharmacology of prostanoids. In: Iloprost in Intensive Care Medicine. Ewert R (Ed.). Uni-Med Verlag, Bremen, Germany, 10-30 (2006).
5. Fisher CA, Kappa JR, Sinha AK et al. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1, on human platelet function. J. Lab. Clin. Med. 109, 184-190 (1987). (Pubitemid 17016406)
6. Belch JF, Green I, McLaren M et al. The effects of intravenous ZK 36374, a stable prostacyclin analogue, on normal volunteers. Prostaglandins 28, 67-71 (1984).
7. Cowley AJ, Heptinstall S, Hampton JR. Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man. Thromb. Haemost. 53, 90-94 (1985). (Pubitemid 15135242)
8. Wharton J, Davie N, Upton PD et al. Prostacyclin analogues differentially inhibits growth of distal and proximal human pulmonary smooth muscle cells. Circulation 102, 3130-3136 (2000).
9. Clapp LH, Finney P, Turcato S et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation 1 Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54, S43-S54 (2009).
10. Badesch DB, Champion HC, Gomez Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54, S55-S66 (2009).
11. Galié N, Hoeper MM, Humbert M et al. Guidelines for diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 30, 2493-2537 (2009).
12. Schulz A. Pharmacology of prostanoids. In: Iloprost in Intensive Care Medicine. Ewert R (Ed.). Uni-Med Verlag, Bremen, Germany, 10-30 (2006).
13. Fisher CA, Kappa JR, Sinha AK et al. Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1, on human platelet function. J. Lab. Clin. Med. 109, 184-190 (1987). (Pubitemid 17016406)
14. Belch JF, Green I, McLaren M et al. The effects of intravenous ZK 36374, a stable prostacyclin analogue, on normal volunteers. Prostaglandins 28, 67-71 (1984).
15. Cowley AJ, Heptinstall S, Hampton JR. Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man. Thromb. Haemost. 53, 90-94 (1985). (Pubitemid 15135242)
16. Wharton J, Davie N, Upton PD et al. Prostacyclin analogues differentially inhibits growth of distal and proximal human pulmonary smooth muscle cells. Circulation 102, 3130-3136 (2000).
17. Clapp LH, Finney P, Turcato S et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell. Mol. Biol. 26, 194-201 (2002). (Pubitemid 34107873)
18. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 31, 891-901 (2008).
19. Hsu HH, Rubin LJ. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother. 6, 1921-1930 (2005). (Pubitemid 41358426)
20. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. Eur. J. Clin. Pharmacol. 32, 597-605 (1987). (Pubitemid 17141209)
21. Schermuly RT, Schulz A, Ghofrani HA et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J. Pharmacol. Exp. Ther. 303, 741-745 (2002). (Pubitemid 35231250)
22. Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 124, 1294-1304 (2003). (Pubitemid 37290038)
23. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338, 1173-1174 (1991).
24. Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med. 124, 820-824 (1996). (Pubitemid 26128412)
25. Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol. 35, 176-182 (2000). (Pubitemid 30061277)
26. Ewert R, Schaper C, Halank M et al. Inhalative iloprost -pharmacology and clinical application. Expert Opin. Pharmacother. 10, 1-13 (2009).
27. Gessler T, Schmehl T, Hoeper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J. 17, 14-19 (2001). (Pubitemid 32600551)
28. Krug S, Sablotzki A, Hammerschmidt S et al. Inhaled iloprost for the control of pulmonary hypertension. Vasc. Health Risk Manag. 5, 465-474 (2009).
29. Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc. Health Risk Manag. 5, 325-331 (2009).
30. Ghofrani HA, Rose F, Schermuly RT et al. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit. Care Med. 30, 2489-2492 (2002). (Pubitemid 35351868)
31. Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104, 1218-1222 (2001). (Pubitemid 32848108)
32. Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136, 515-522 (2002). (Pubitemid 34252285)
33. Petkov V, Ziesche R, Mosgoeller W et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 56, 734-736 (2001). (Pubitemid 32831702)
34. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76, 135-141 (1987). (Pubitemid 17093201)
35. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 40S-47S (2004).
36. Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111, 3105-3111 (2005). (Pubitemid 40847788)
37. Montani D, Savale L, Natali D et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur. Heart J. 31, 1898-1907 (2010).
38. Jing ZC, Jiang X, Han ZY et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 33, 1354-1360 (2009).
39. Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir. Med. 104, 481-496 (2010).
40. Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med. 342, 1866-1870 (2000). (Pubitemid 30419050)
41. Ewert R, Wensel R, Opitz CF. Aerosolized iloprost for primary pulmonary hypertension. N. Engl. J. Med. 343, 1421-1422 (2000).
42. Ewert R, Opitz C, Wensel R et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol. 89, 987-999 (2000).
43. Machherndl S, Kneussl M, Baumgartner H et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur. Respir. J. 17, 8-13 (2001). (Pubitemid 32600550)
44. Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann. Intern. Med. 132, 435-443 (2000). (Pubitemid 30149040)
45. Olschewski H, Simonneau G, Galiè N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347, 322-329 (2002). (Pubitemid 34815354)
46. Hoeper MM, Taha N, Bekjarova A et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur. Respir. J. 22, 330-334 (2003). (Pubitemid 36987006)
47. Seyfarth HJ, Pankau H, Hammerschmidt S et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 28, 709-713 (2005). (Pubitemid 41140500)
48. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42, 158-164 (2003). (Pubitemid 36760778)
49. Beyer S, Speich R, Fischler M et al. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med. Wkly 136, 114-118 (2006).
50. Durongpisitkul K, Jakrapanichakul D, Laohaprasitiporn D et al. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease. J. Med. Assoc. Thai. 88(Suppl. 8), S60-S65 (2005). (Pubitemid 43175622)
51. McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 174, 1257-1263 (2006). (Pubitemid 44924827)
52. Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 28, 691-694 (2006). (Pubitemid 46331988)
53. Olschewski H, Hoeper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir. Med. 104, 731-740 (2010).
54. Reichenberger F, Mainwood A, Doughty N et al. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension. Respir. Med. 101, 217-222 (2007). (Pubitemid 46075984)
55. Ivy DD, Doran AK, Smith KJ et al. Short-and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 51, 161-169 (2008).
56. Opitz CF, Wensel R, Winkler J et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J. 26, 1895-1902 (2005). (Pubitemid 41253303)
57. McLaughlin VV, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 55, 1915-1922 (2010).
58. Garin MC, Clark L, Chumney EC et al. Cost-utility of treatments for pulmonary arterial hypertension a markov state-transition decision analysis model. Clin. Drug Investig. 29, 635-646 (2009).
59. Hoeper MM, Seyfarth HJ, Hoeffken G et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur. Respir. J. 30, 1096-1102 (2007). (Pubitemid 351194755)
60. Launay D, Hachulla E, Hatron PY et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J. Rheumatol. 28, 2252-2256 (2001). (Pubitemid 32947871)
61. Fruhwald FM, Kjellstrom B, Perthold W et al. Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost. Chest 124, 351-359 (2003). (Pubitemid 36851373)
62. Melgosa MT, Ricci GL, García-Pagan JC et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl. 16, 348-356 (2010).
63. Reichenberger F, Mainwood A, Morrell NW, Parameshwar J, Pepke-Zaba J. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Pulm. Pharmacol. Ther. DOI: 10.1016/j.pupt.2010.06.004 (2010) (Epub ahead of print).
64. Baughman RP, Judson MA, Lower EE et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc. Diffuse Lung Dis. 26, 110-120 (2009).